

MRP3/ABCC3 (D8V8J) Rabbit mAb

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W, IP	H M R	Endogenous	160-220	Rabbit IgG	#O15438	8714

Product Usage Information**Application**

Western Blotting
Immunoprecipitation

Dilution

1:1000
1:50

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.

Specificity/Sensitivity

MRP3/ABCC3 (D8V8J) Rabbit mAb recognizes endogenous levels of total MRP3 protein.

Source / Purification

Monoclonal antibody is produced by immunizing animals with recombinant protein surrounding Gly870 of human MRP3 protein.

Background

MRP3/ABCC3 belongs to the super family of ATP-binding cassette (ABC) transporters. It is a member of the MRP subfamily that is expressed in various organs including liver, gallbladder, small intestine, colon, kidney, and adrenal gland (1-3). MRP3 is involved in multi-drug resistance (1). It facilitates the efflux of organic anions including monoanionic bile acid and anti-cancer reagents such as etoposide and paclitaxel from liver and small intestine into blood (4-7). Expression of MRP3 is increased in the cholestatic human and rat liver, suggesting its role in cholehepatic and enterohepatic bile circulation and in protecting liver from toxic bile salts (2,8). MRP3 expression is also upregulated in people with Dubin-Johnson Syndrome (DJS) who lack functional MRP2 in the liver, which implicates the compensatory role of MRP3 in the absence of functional MRP2 (4).

Elevated expression of MRP3 has been detected in various cancer types such as hepatocellular carcinomas, primary ovarian cancer, and adult acute lymphoblastic leukemia (ALL) (9-11). Overexpression of MRP3 was reported to be a prognostic factor in ALL and adult acute myeloid leukemia (AML) (11,12).

Background References

1. Uchiumi, T. et al. (1998) *Biochem Biophys Res Commun* 252, 103-10.
2. Scheffer, G.L. et al. (2002) *Lab Invest* 82, 193-201.
3. Kiuchi, Y. et al. (1998) *FEBS Lett* 433, 149-52.
4. König, J. et al. (1999) *Hepatology* 29, 1156-63.
5. Zelcer, N. et al. (2001) *J Biol Chem* 276, 46400-7.
6. Belinsky, M.G. et al. (2005) *Mol Pharmacol* 68, 160-8.
7. Dickerson, W.G. (1992) *Dent Today* 11, 54-5.
8. Soroka, C.J. et al. (2001) *Hepatology* 33, 783-91.
9. Nies, A.T. et al. (2001) *Int J Cancer* 94, 492-9.
10. Ohishi, Y. et al. (2002) *Clin Cancer Res* 8, 3767-75.
11. Plasschaert, S.L. et al. (2005) *Clin Cancer Res* 11, 8661-8.
12. Benderra, Z. et al. (2005) *Clin Cancer Res* 11, 7764-72.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween@ 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation

Cross-Reactivity Key

H: Human **M:** Mouse **R:** Rat

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.